Powder: -20°C for 3 years | In solvent: -80°C for 1 year
cRIPGBM, a proapoptotic derivative of RIPGBM, selectively induces apoptosis in GBM cancer stem cells (CSCs) by targeting receptor-interacting protein kinase 2 (RIPK2), demonstrating an EC50 of 68 nM in GBM-1 cells [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 6-8 weeks | $ 2,140.00 | |
50 mg | 6-8 weeks | $ 2,785.00 | |
100 mg | 6-8 weeks | $ 3,520.00 |
Description | cRIPGBM, a proapoptotic derivative of RIPGBM, selectively induces apoptosis in GBM cancer stem cells (CSCs) by targeting receptor-interacting protein kinase 2 (RIPK2), demonstrating an EC50 of 68 nM in GBM-1 cells [1]. |
Molecular Weight | 411.45 |
Formula | C26H20FN2O2 |
CAS No. | 2361988-76-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
cRIPGBM 2361988-76-1 Apoptosis TNF inhibitor inhibit